Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808288 · ClinicalTrials.gov registry record · Phase 2
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
A Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 405
- Enrollment target
- 20
- Study locations
NCT00808288: Completed Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases, sponsored by Pfizer.
NCT00808288 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases that has completed, run by Pfizer. The registered enrollment target is 405 participants, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00808288, a Phase 2 study of Pulmonary Disease, Chronic Obstructive and Lung Diseases, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 405 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salmeterol
- DRUG PF-00610355
- DRUG PF - 00610355
- DRUG PF- 00610355
Study Locations (20)
Florida
- Pfizer Investigational Site - Daytona Beach
- Pfizer Investigational Site - Ormond Beach
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Trinity
Minnesota
- Pfizer Investigational Site - Fridley
- Pfizer Investigational Site - Minneapolis
- Pfizer Investigational Site - Rochester
Ohio
- Pfizer Investigational Site - Cincinnati
- Pfizer Investigational Site - Cincinnati
- Pfizer Investigational Site - Cincinnati
California
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - Spring Valley
Kansas
- Pfizer Investigational Site - Overland Park
- Pfizer Investigational Site - Overland Park
Alabama
- Pfizer Investigational Site - Fairhope
Colorado
- Pfizer Investigational Site - Wheat Ridge
Georgia
- Pfizer Investigational Site - Austell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00808288 record still lists
NCT00808288 is an interventional study that assigns participants to a tested intervention. The registered 405 participants enrollment target is mid-sized for trials with a published cap, below the 1,039-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (61% lower).
The record links to 3 conditions, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT00808288 names 20 study sites across 11 states, led by Florida, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT00808288 about?
NCT00808288 is a clinical study titled "A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.". To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)
What is the current status of trial NCT00808288?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 405 participants. The study started on 2010-03. Estimated completion is 2010-12.
What conditions does trial NCT00808288 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Lung Diseases, Lung Diseases, Obstructive.
What interventions are being tested in trial NCT00808288?
The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), PF-00610355 (DRUG), PF - 00610355 (DRUG), PF- 00610355 (DRUG).
Who is sponsoring clinical trial NCT00808288?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808288 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00808288's enrollment target sits among peer trials
405 31st of 74 higher than 44 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
-
Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
- NCT07066657 · 405 participants · Phase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia